Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Azemiglitazone - Cirius Therapeutics

Next Previous
Drug Profile

Azemiglitazone - Cirius Therapeutics

Alternative Names: CIR-0602K; MSDC-0602; MSDC-0602 potassium; MSDC-0602K

Latest Information Update: 16 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Metabolic Solutions Development Company
  • Developer Cirius Therapeutics; Metabolic Solutions Development Company; University of Virginia School of Medicine
  • Class Antihyperglycaemics; Hepatoprotectants; Insulin sensitisers; Obesity therapies; Small molecules; Thiazolidinediones; Urologics
  • Mechanism of Action Mitochondrial membrane transport protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis; Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Clinical Phase Unknown Obesity
  • No development reported Polycystic kidney disease

Most Recent Events

  • 16 Apr 2026 Cirius Therapeutics plans a EOP2 meetings with the FDA (Cirius Therapeutics website, April 2026)
  • 22 Feb 2026 Phase-II clinical trials in Type 1 diabetes mellitus (Treatment-experienced) in USA (PO) (NCT07186660)
  • 09 Dec 2025 Cirius Therapeutics in collaboration with University of Virginia plans a phase IIa trial for Type I diabetes mellitus in USA (PO) in fourth quarter of 2025 (NCT07186660)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top